Protection Against Visible Light by Dihydroxyacetone in Erythropoietic Protoporphyria

Protection Against Visible Light by Dihydroxyacetone in Erythropoietic Protoporphyria

What is the visible light protective effect of dihydroxyacetone in individuals with erythropoietic protoporphyria? This will be tested in this randomized blinded placebo controlled study.

Inclusion Criteria:

• Diagnosed with erythropoietic protoporphyria
• At least 18 years of age
• Obtainment of written informed consent

Exclusion Criteria:

• Pregnant or breastfeeding
• Use of dihydroxyacetone at the treatment or placebo fields within the last two week
• Sun exposure of the treatment or placebo fields within the last two week
• Use of suncreen or other local treatment on the treatment or placebo fields during the study period (two days)
• Allergy to adhesive bandages, dihydroxyacetone or lotion